112 related articles for article (PubMed ID: 10966754)
1. 3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
Derrick I; Neilan CL; Andes J; Husbands SM; Woods JH; Traynor JR; Lewis JW
J Med Chem; 2000 Aug; 43(17):3348-50. PubMed ID: 10966754
[TBL] [Abstract][Full Text] [Related]
2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.
Rennison D; Moynihan H; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2006 Oct; 49(20):6104-10. PubMed ID: 17004724
[TBL] [Abstract][Full Text] [Related]
5. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
6. Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist.
Spetea M; Tóth F; Schütz J; Otvös F; Tóth G; Benyhe S; Borsodi A; Schmidhammer H
Eur J Neurosci; 2003 Jul; 18(2):290-5. PubMed ID: 12887410
[TBL] [Abstract][Full Text] [Related]
7. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
9. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
Thomas JB; Atkinson RN; Rothman RB; Fix SE; Mascarella SW; Vinson NA; Xu H; Dersch CM; Lu Y; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2001 Aug; 44(17):2687-90. PubMed ID: 11495579
[TBL] [Abstract][Full Text] [Related]
10. Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and their enantiomers.
Furness MS; Zhang X; Coop A; Jacobson AE; Rothman RB; Dersch CM; Xu H; Porreca F; Rice KC
J Med Chem; 2000 Aug; 43(16):3193-6. PubMed ID: 10956228
[TBL] [Abstract][Full Text] [Related]
11. Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives.
Wentland MP; Duan W; Cohen DJ; Bidlack JM
J Med Chem; 2000 Sep; 43(19):3558-65. PubMed ID: 11000010
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
[TBL] [Abstract][Full Text] [Related]
13. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
14. Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
Moynihan HA; Derrick I; Broadbear JH; Greedy BM; Aceto MD; Harris LS; Purington LC; Thomas MP; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2012 Nov; 55(22):9868-74. PubMed ID: 23043264
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
16. Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
Iyer MR; Rothman RB; Dersch CM; Jacobson AE; Rice KC
Bioorg Med Chem; 2013 Jun; 21(11):3298-309. PubMed ID: 23618710
[TBL] [Abstract][Full Text] [Related]
17. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
19. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
20. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
